Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome.

Kraisin S, Verhenne S, Pham TT, Martinod K, Tersteeg C, Vandeputte N, Deckmyn H, Vanhoorelbeke K, Van den Steen PE, De Meyer SF.

J Thromb Haemost. 2019 May 17. doi: 10.1111/jth.14485. [Epub ahead of print]

PMID:
31099973
2.

Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance.

Staessens S, Denorme F, François O, Desender L, Dewaele T, Vanacker P, Deckmyn H, Vanhoorelbeke K, Andersson T, De Meyer SF.

Haematologica. 2019 May 2. pii: haematol.2019.219881. doi: 10.3324/haematol.2019.219881. [Epub ahead of print]

3.

Neutrophil Extracellular Traps in Arterial and Venous Thrombosis.

Laridan E, Martinod K, De Meyer SF.

Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi: 10.1055/s-0038-1677040. Epub 2019 Jan 11. Review.

PMID:
30634198
4.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.

5.

von Willebrand factor deficiency does not influence angiotensin II-induced abdominal aortic aneurysm formation in mice.

Portier I, Martinod K, Desender L, Vandeputte N, Deckmyn H, Vanhoorelbeke K, De Meyer SF.

Sci Rep. 2018 Nov 9;8(1):16645. doi: 10.1038/s41598-018-35029-8.

6.

Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.

Deconinck S, Tersteeg C, Bailleul E, Delrue L, Vandeputte N, Pareyn I, Itzhar-Baikian N, Deckmyn H, De Meyer SF, Vanderheyden M, Vanhoorelbeke K.

Res Pract Thromb Haemost. 2018 Oct 8;2(4):762-766. doi: 10.1002/rth2.12150. eCollection 2018 Oct.

7.

Clot Pathophysiology: Why Is It Clinically Important?

Brouwer PA, Brinjikji W, De Meyer SF.

Neuroimaging Clin N Am. 2018 Nov;28(4):611-623. doi: 10.1016/j.nic.2018.06.005. Epub 2018 Sep 15. Review.

PMID:
30322597
8.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.

9.

Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.

South K, Denorme F, Salles-Crawley II, De Meyer SF, Lane DA.

J Thromb Haemost. 2018 Nov;16(11):2289-2299. doi: 10.1111/jth.14275. Epub 2018 Oct 24.

10.

Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors.

Vermeersch E, Liénart S, Collignon A, Lucas S, Gallimore A, Gysemans C, Unutmaz D, Vanhoorelbeke K, De Meyer SF, Maes W, Deckmyn H.

Cell Immunol. 2018 Oct;332:129-133. doi: 10.1016/j.cellimm.2018.07.011. Epub 2018 Jul 30.

PMID:
30093071
11.

Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13.

Schelpe AS, Orlando C, Ercig B, Geeroms C, Pareyn I, Vandeputte N, Velásquez Pereira LC, Roose E, Fostier K, Nicolaes GAF, Deckmyn H, De Meyer SF, Vanhoorelbeke K, Jochmans K.

Eur J Haematol. 2018 May 15. doi: 10.1111/ejh.13094. [Epub ahead of print]

PMID:
29763513
12.

Improved molecular platform for the gene therapy of rare diseases by liver protein secretion.

Quiviger M, Giannakopoulos A, Verhenne S, Marie C, Stavrou EF, Vanhoorelbeke K, Izsvák Z, De Meyer SF, Athanassiadou A, Scherman D.

Eur J Med Genet. 2018 Nov;61(11):723-728. doi: 10.1016/j.ejmg.2018.04.010. Epub 2018 Apr 26. Review.

PMID:
29704684
13.

Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice.

Witsch T, Martinod K, Sorvillo N, Portier I, De Meyer SF, Wagner DD.

J Am Heart Assoc. 2018 Jan 24;7(3). pii: e007004. doi: 10.1161/JAHA.117.007004.

14.

High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease.

Portier I, Vanhoorelbeke K, Verhenne S, Pareyn I, Vandeputte N, Deckmyn H, Goldenberg DS, Samal HB, Singh M, Ivics Z, Izsvák Z, De Meyer SF.

J Thromb Haemost. 2018 Mar;16(3):592-604. doi: 10.1111/jth.13938. Epub 2018 Jan 31.

PMID:
29288565
15.

An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.

Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, Greinacher A, Deckmyn H, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

J Thromb Haemost. 2018 Feb;16(2):378-388. doi: 10.1111/jth.13922. Epub 2018 Jan 23.

PMID:
29222940
16.

Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets.

Quach ME, Dragovich MA, Chen W, Syed AK, Cao W, Liang X, Deng W, De Meyer SF, Zhu G, Peng J, Ni H, Bennett CM, Hou M, Ware J, Deckmyn H, Zhang XF, Li R.

Blood. 2018 Feb 15;131(7):787-796. doi: 10.1182/blood-2017-05-784975. Epub 2017 Dec 4.

17.

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.

Tersteeg C, Joly BS, Gils A, Lijnen R, Deckmyn H, Declerck PJ, Plaimauer B, Coppo P, Veyradier A, Maas C, De Meyer SF, Vanhoorelbeke K.

J Thromb Haemost. 2017 Dec;15(12):2432-2442. doi: 10.1111/jth.13859. Epub 2017 Oct 27.

PMID:
28981198
18.

Neutrophil extracellular traps in ischemic stroke thrombi.

Laridan E, Denorme F, Desender L, François O, Andersson T, Deckmyn H, Vanhoorelbeke K, De Meyer SF.

Ann Neurol. 2017 Aug;82(2):223-232. doi: 10.1002/ana.24993. Epub 2017 Aug 11.

PMID:
28696508
19.

Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.

Denorme F, Kraft P, Pareyn I, Drechsler C, Deckmyn H, Vanhoorelbeke K, Kleinschnitz C, De Meyer SF.

PLoS One. 2017 Jun 7;12(6):e0179258. doi: 10.1371/journal.pone.0179258. eCollection 2017.

20.

Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions.

De Meyer SF, Andersson T, Baxter B, Bendszus M, Brouwer P, Brinjikji W, Campbell BC, Costalat V, Dávalos A, Demchuk A, Dippel D, Fiehler J, Fischer U, Gilvarry M, Gounis MJ, Gralla J, Jansen O, Jovin T, Kallmes D, Khatri P, Lees KR, López-Cancio E, Majoie C, Marquering H, Narata AP, Nogueira R, Ringleb P, Siddiqui A, Szikora I, Vale D, von Kummer R, Yoo AJ, Hacke W, Liebeskind DS; Clot Summit Group.

Int J Stroke. 2017 Aug;12(6):606-614. doi: 10.1177/1747493017709671. Epub 2017 May 23. Review.

PMID:
28534706
21.

Platelet granules in vascular integrity.

De Meyer SF.

Blood. 2017 Mar 23;129(12):1573-1574. doi: 10.1182/blood-2017-02-763540. No abstract available.

22.

The role of platelet and endothelial GARP in thrombosis and hemostasis.

Vermeersch E, Denorme F, Maes W, De Meyer SF, Vanhoorelbeke K, Edwards J, Shevach EM, Unutmaz D, Fujii H, Deckmyn H, Tersteeg C.

PLoS One. 2017 Mar 9;12(3):e0173329. doi: 10.1371/journal.pone.0173329. eCollection 2017.

23.

Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.

Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):836-844. doi: 10.1161/ATVBAHA.116.308680. Epub 2017 Mar 2.

PMID:
28254814
24.

N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura.

Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I, Vandenbulcke A, Plaimauer B, Lamprecht S, Deckmyn H, Lopez JA, De Meyer SF, Vanhoorelbeke K.

Blood. 2017 Feb 23;129(8):1030-1038. doi: 10.1182/blood-2016-09-738856. Epub 2016 Dec 23.

25.

Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.

Deforche L, Tersteeg C, Roose E, Vandenbulcke A, Vandeputte N, Pareyn I, De Cock E, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

PLoS One. 2016 Aug 1;11(8):e0160388. doi: 10.1371/journal.pone.0160388. eCollection 2016.

26.

Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.

Denorme F, Wyseure T, Peeters M, Vandeputte N, Gils A, Deckmyn H, Vanhoorelbeke K, Declerck PJ, De Meyer SF.

Stroke. 2016 Sep;47(9):2419-22. doi: 10.1161/STROKEAHA.116.014091. Epub 2016 Jul 28.

PMID:
27470988
27.

Platelet sequestration and activation during GalTKO.hCD46 pig lung perfusion by human blood is primarily mediated by GPIb, GPIIb/IIIa, and von Willebrand Factor.

Burdorf L, Riner A, Rybak E, Salles II, De Meyer SF, Shah A, Quinn KJ, Harris D, Zhang T, Parsell D, Ali F, Schwartz E, Kang E, Cheng X, Sievert E, Zhao Y, Braileanu G, Phelps CJ, Ayares DL, Deckmyn H, Pierson RN 3rd, Azimzadeh AM, Dandro A, Karavi K.

Xenotransplantation. 2016 May;23(3):222-236. doi: 10.1111/xen.12236. Epub 2016 May 18. Erratum in: Xenotransplantation. 2016 Sep;23(5):423.

28.

The VWF-GPIb axis in ischaemic stroke: lessons from animal models.

Denorme F, De Meyer SF.

Thromb Haemost. 2016 Sep 27;116(4):597-604. doi: 10.1160/TH16-01-0036. Epub 2016 Mar 31. Review.

PMID:
27029413
29.

ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice.

Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, François O, Andersson T, Deckmyn H, Scheiflinger F, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF.

Blood. 2016 May 12;127(19):2337-45. doi: 10.1182/blood-2015-08-662650. Epub 2016 Feb 29.

30.

Thromboinflammation in Stroke Brain Damage.

De Meyer SF, Denorme F, Langhauser F, Geuss E, Fluri F, Kleinschnitz C.

Stroke. 2016 Apr;47(4):1165-72. doi: 10.1161/STROKEAHA.115.011238. Epub 2016 Jan 19. Review. No abstract available.

PMID:
26786115
31.

ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.

Tersteeg C, Verhenne S, Roose E, Schelpe AS, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

Expert Rev Hematol. 2016;9(2):209-21. doi: 10.1586/17474086.2016.1122515. Epub 2015 Dec 8. Review.

PMID:
26581428
32.

Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.

Deforche L, Roose E, Vandenbulcke A, Vandeputte N, Feys HB, Springer TA, Mi LZ, Muia J, Sadler JE, Soejima K, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.

J Thromb Haemost. 2015 Nov;13(11):2063-75. doi: 10.1111/jth.13149. Epub 2015 Oct 20.

33.

Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.

Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K.

Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2336-42. doi: 10.1161/ATVBAHA.115.306014. Epub 2015 Sep 3.

PMID:
26338302
34.

Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice.

Verhenne S, Denorme F, Libbrecht S, Vandenbulcke A, Pareyn I, Deckmyn H, Lambrecht A, Nieswandt B, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF.

Blood. 2015 Oct 1;126(14):1715-22. doi: 10.1182/blood-2015-03-632901. Epub 2015 Jul 24.

35.

Choline Transporter-Like Protein-2: New von Willebrand Factor-Binding Partner Involved in Antibody-Mediated Neutrophil Activation and Transfusion-Related Acute Lung Injury.

Bayat B, Tjahjono Y, Berghöfer H, Werth S, Deckmyn H, De Meyer SF, Sachs UJ, Santoso S.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1616-22. doi: 10.1161/ATVBAHA.115.305259. Epub 2015 Apr 30.

PMID:
25931511
36.

Response to letter regarding article, "plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2015 Jan 13;131(2):e19-20. doi: 10.1161/CIRCULATIONAHA.114.012802. No abstract available.

PMID:
25583061
37.

Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke.

Wyseure T, Rubio M, Denorme F, Martinez de Lizarrondo S, Peeters M, Gils A, De Meyer SF, Vivien D, Declerck PJ.

Blood. 2015 Feb 19;125(8):1325-32. doi: 10.1182/blood-2014-07-588319. Epub 2014 Dec 24.

38.

The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice.

De Cock E, Hermans C, De Raeymaecker J, De Ceunynck K, De Maeyer B, Vandeputte N, Vandenbulcke A, Deckmyn H, Rottensteiner H, De Maeyer M, De Meyer SF, Vanhoorelbeke K.

J Thromb Haemost. 2015 Feb;13(2):283-92. doi: 10.1111/jth.12804. Epub 2015 Jan 17.

39.

Single particle tracking of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type-1 repeats) molecules on endothelial von Willebrand factor strings.

De Ceunynck K, Rocha S, De Meyer SF, Sadler JE, Uji-i H, Deckmyn H, Hofkens J, Vanhoorelbeke K.

J Biol Chem. 2014 Mar 28;289(13):8903-15. doi: 10.1074/jbc.M113.535963. Epub 2014 Feb 18.

40.

Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21.

PMID:
24449821
41.

VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.

Savchenko AS, Borissoff JI, Martinod K, De Meyer SF, Gallant M, Erpenbeck L, Brill A, Wang Y, Wagner DD.

Blood. 2014 Jan 2;123(1):141-8. doi: 10.1182/blood-2013-07-514992. Epub 2013 Nov 7.

42.

Animal models for thrombotic thrombocytopenic purpura.

Vanhoorelbeke K, De Meyer SF.

J Thromb Haemost. 2013 Jun;11 Suppl 1:2-10. doi: 10.1111/jth.12255. Review.

43.

Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice.

Suidan GL, Brill A, De Meyer SF, Voorhees JR, Cifuni SM, Cabral JE, Wagner DD.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2112-20. doi: 10.1161/ATVBAHA.113.301362. Epub 2013 Jul 3.

44.

Unwinding the von Willebrand factor strings puzzle.

De Ceunynck K, De Meyer SF, Vanhoorelbeke K.

Blood. 2013 Jan 10;121(2):270-7. doi: 10.1182/blood-2012-07-442285. Epub 2012 Oct 23. Review.

45.

Inhibitors of the interactions between collagen and its receptors on platelets.

Deckmyn H, De Meyer SF, Broos K, Vanhoorelbeke K.

Handb Exp Pharmacol. 2012;(210):311-37. doi: 10.1007/978-3-642-29423-5_13. Review.

PMID:
22918737
46.

Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carroll MC, Schiviz A, Dietrich B, Rottensteiner H, Scheiflinger F, Wagner DD.

Blood. 2012 Dec 20;120(26):5217-23. doi: 10.1182/blood-2012-06-439935. Epub 2012 Aug 22.

47.

Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'.

Kraft P, De Meyer SF, Kleinschnitz C.

J Cereb Blood Flow Metab. 2012 Oct;32(10):1831-40. doi: 10.1038/jcbfm.2012.108. Epub 2012 Jul 18. Review.

48.

Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice.

Brill A, Yesilaltay A, De Meyer SF, Kisucka J, Fuchs TA, Kocher O, Krieger M, Wagner DD.

Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1841-7. doi: 10.1161/ATVBAHA.112.252130. Epub 2012 May 31.

49.

Extracellular chromatin is an important mediator of ischemic stroke in mice.

De Meyer SF, Suidan GL, Fuchs TA, Monestier M, Wagner DD.

Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1884-91. doi: 10.1161/ATVBAHA.112.250993. Epub 2012 May 24.

50.

von Willebrand factor: an emerging target in stroke therapy.

De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C.

Stroke. 2012 Feb;43(2):599-606. doi: 10.1161/STROKEAHA.111.628867. Epub 2011 Dec 15. Review.

Supplemental Content

Loading ...
Support Center